Compare Firy Inc. (FIRY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Firy Inc. trades at $8.41 (market cap $125.48M), while Vertex Pharmaceuticals Incorporated trades at $481.63 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 965× Firy Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Firy Inc. nearer its low. Which is the better fit depends on your goals.
| FIRY | VRTX | |
|---|---|---|
Market Cap | $125.48M | $121.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $529.59 |
52-Week Low | $2.28 | $366.54 |
Enterprise Value | $69.16M | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $8.04, down 4.74% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. The company recently rebranded and reported Q1 2026 results showing revenue growth to $104.5M but persistent losses with a net margin of -57.48%. Cash flow remains negative at -$86.41M for 2025, though operating losses have narrowed from 2022 peaks.
Outlook is cautious; while technicals suggest near-term support at $8, fundamental challenges include deep losses and negative cash flow. Analyst sentiment is mixed with 60% hold ratings. Key risks are profitability timeline and competitive pressure, but rebranding and legal victories may support long-term turnaround if execution improves.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
